Case Study

Enable Oral Delivery Of Synthetic Oligosaccharides

Source: Catalent

Synthetic oligosaccharides are used in clinical practice as anticoagulants. Due to their poor oral bioavailability, oligosaccharides — along with most pharmaceutical macromolecules — are formulated as solutions or suspensions and delivered by invasive intravenous (IV) or subcutaneous injection. When oral bioavailability is increased, macromolecule can potentially be converted from injectable to oral drug delivery. This case study demonstrates how OptiGel ™ Bio technology significantly increases oral bioavailability of a synthetic oligosaccharide, thus enabling oral conversion.